Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Stem Cell Therapy: A Ray of Hope for Diabetics and Researchers
Apr 25, 2007
The results of the stem cell therapy given to teenagers and young adults suffering from Type-1 diabetes were described to be "very encouraging" by the two researchers - Richard Burt of Northwestern University Feinberg School of Medicine, Chicago, and University of Sao Paulo’s Julio Voltarelli. The patients, on whom the test was done, could discontinue taking insulin following the successful knock out of their malfunctioning immune systems. The treatment also reconstructed them from their own stem cells.
Just after giving an injection of stem cells, a large number of patients did not feel the need to take another insulin injection, as the effect of the first injection lasted from one to 35 months.
Often, this type of diabetes (Type-1) is diagnosed in young adults or children. It’s a gene linked disorder which affects approximately1.4 million Americans, as per the US Centers for Disease Control & Prevention. Even if controlled by taking insulin injections daily, Type-1 diabetes may result in complications such as heart disease, high blood pressure, limbs’ amputation, and circulation problems.
A treatment of Type-1 diabetes, which doesn’t require multiple injections of insulin to be pricked everyday, is sure to offer a hope of a nearly needle free life for people suffering from this fatal and incapacitating disease.
The multi billion-dollar market of insulin can also be severely impacted by the successful stem cell treatment – a market wherein a barrage of various treatment revolutions either have or may continue to remain lackluster. For example, Exubera – the world’s 1st and perhaps only inhaled insulin product developed by Pfizer – was once seen as a potential breakthrough drug. Sales of Exubera however have been particularly disappointing for pharmaceutical giant.
RNCOS report "Insulin Delivery Systems Market Analysis (2007-2010)" notifies, "Current ambiance in insulin market comprises of strong marketing plus clinical support in favor of the newly launched products. Drug delivery products’ sales will likely increase by 100% in the coming five years, since technologies being researched & developed currently will attain fruition and get commercialized by that time. Presently, special drug delivery technology’s market value is US$ 50 Billion per year, i.e. 12.5% of global pharmaceutical sales."
This research report "Insulin Delivery Systems Market Analysis (2007-2010)" helps clients in analyzing the opportunities critical to the growth of Insulin Delivery Systems in the World. The report addresses some interesting issues for today’s Global business environment, such as evaluation of current market trends, discussion about the leading edge technologies, scope of the major insulin delivery systems all over the world, analysis of various challenges and opportunities before the industry, etc.
For more information visit: http://www.rncos.com/Report/IM509.htm
Some of our Related Reports are as follows:Â
Related Releases are as follows:
- Green Go to Derma Clinical Trial - How will it Shape Industry?
- Liquid Biopsy Paving the Way to Growth through Strategic Transactions
- India- A Largely Untapped Market for NIPT
- Government Initiatives Promoting the Indian Healthcare Sector
- Clinical Chemistry Testing Major Driver for US Clinical Laboratory Testing Market
Media Citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2014, RNCOS, 2002-2014
About Us
Terms & Policy
Contact